Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod in Rett Syndrome
NCT02061137Phase 2Completed
- Sponsor
- University Hospital Basel
- Start
- Aug 2013
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fingolimod in Rett syndrome (RTT), sponsored by University Hospital Basel. Primary endpoints: Levels of Brain derived neurotrophic factor (BDNF) in blood and cerebrospinal fluid at 12 months and Safety and Efficacy at 12 months. Started Aug 2013; status: completed.
02
Drugs
fingolimod
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT02061137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061137.